Literature DB >> 2241292

Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.

Y Shapira1, F Mor, A Friedler, A J Wysenbeek, A Weinberger.   

Abstract

A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome. Albumin and furosemide given intravenously was ineffective. Captopril administered in a daily dose of 62.5 mg was associated with a reduction in proteinuria from 28 g/24 hours to 11.5 g/24 hours over 10 weeks, resulting in a weight reduction of 16 kg. This was achieved with relative preservation of renal function. Captopril should be considered in the treatment of intractable proteinuria in patients with lupus nephritis, or when cytotoxic drugs are refused, because of its efficacy and relative safety. Captopril should, however, be used as an adjunct and not as a substitute for standard treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2241292      PMCID: PMC1004213          DOI: 10.1136/ard.49.9.725

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria.

Authors:  E J Lewis
Journal:  Am J Kidney Dis       Date:  1987-07       Impact factor: 8.860

2.  Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.

Authors:  H Trachtman; B Gauthier
Journal:  J Pediatr       Date:  1988-02       Impact factor: 4.406

3.  Antiproteinuric effect of captopril in primary glomerular disease.

Authors:  G Lagrue; R Robeva; J Laurent
Journal:  Nephron       Date:  1987       Impact factor: 2.847

4.  Reduction of proteinuria by angiotensin converting enzyme inhibition.

Authors:  J E Heeg; P E de Jong; G K van der Hem; D de Zeeuw
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

5.  Effect of captopril on heavy proteinuria in azotemic diabetics.

Authors:  Y Taguma; Y Kitamoto; G Futaki; H Ueda; H Monma; M Ishizaki; H Takahashi; H Sekino; Y Sasaki
Journal:  N Engl J Med       Date:  1985-12-26       Impact factor: 91.245

6.  Captopril and immune regulation.

Authors:  J F Delfraissy; P Galanaud; J F Balavoine; C Wallon; J Dormont
Journal:  Kidney Int       Date:  1984-06       Impact factor: 10.612

7.  Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice.

Authors:  H Herlitz; A Tarkowski; C Svalander; R Volkmann; G Westberg
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

8.  Captopril treatment of hypertension and renal failure in systemic lupus erythematosus.

Authors:  H Herlitz; C Edenö; H Mulec; G Westberg; M Aurell
Journal:  Nephron       Date:  1984       Impact factor: 2.847

  8 in total
  2 in total

Review 1.  Treatment of severe proliferative lupus nephritis: the current state.

Authors:  C C Mok; R W S Wong; K N Lai
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.

Authors:  Deijanira Alves De Albuquerque; Vijay Saxena; David E Adams; Gregory P Boivin; Hermine I Brunner; David P Witte; Ram Raj Singh
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.